These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 18514200)

  • 21. [Current topics in the regulation of prostanoids--3. Prostanoid synthases and prostanoid receptors].
    Ohara M; Sawa T
    Masui; 1999 Jan; 48(1):42-7. PubMed ID: 10036888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation.
    Hata AN; Breyer RM
    Pharmacol Ther; 2004 Aug; 103(2):147-66. PubMed ID: 15369681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiological regulation of prostaglandins in the kidney.
    Hao CM; Breyer MD
    Annu Rev Physiol; 2008; 70():357-77. PubMed ID: 17988207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interactions between thromboxane A₂, thromboxane/prostaglandin (TP) receptors, and endothelium-derived hyperpolarization.
    Ellinsworth DC; Shukla N; Fleming I; Jeremy JY
    Cardiovasc Res; 2014 Apr; 102(1):9-16. PubMed ID: 24469536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications.
    Basu S
    Antioxid Redox Signal; 2008 Aug; 10(8):1405-34. PubMed ID: 18522490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases.
    Praticò D; Rokach J; Lawson J; FitzGerald GA
    Chem Phys Lipids; 2004 Mar; 128(1-2):165-71. PubMed ID: 15037161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases.
    Aviram M
    Free Radic Res; 2000 Nov; 33 Suppl():S85-97. PubMed ID: 11191279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease.
    Gounopoulos P; Merki E; Hansen LF; Choi SH; Tsimikas S
    Minerva Cardioangiol; 2007 Dec; 55(6):821-37. PubMed ID: 18091649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The isoprostanoid pathway in plants.
    Thoma I; Krischke M; Loeffler C; Mueller MJ
    Chem Phys Lipids; 2004 Mar; 128(1-2):135-48. PubMed ID: 15037159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostanoid receptors and their biological actions.
    Negishi M; Sugimoto Y; Ichikawa A
    Prog Lipid Res; 1993; 32(4):417-34. PubMed ID: 8309950
    [No Abstract]   [Full Text] [Related]  

  • 31. Prostaglandins in the kidney: developments since Y2K.
    Nasrallah R; Clark J; Hébert RL
    Clin Sci (Lond); 2007 Oct; 113(7):297-311. PubMed ID: 17760567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostanoids and their receptors that modulate dendritic cell-mediated immunity.
    Gualde N; Harizi H
    Immunol Cell Biol; 2004 Aug; 82(4):353-60. PubMed ID: 15283844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isoprostanes: generation, pharmacology, and roles in free-radical-mediated effects in the lung.
    Janssen LJ
    Pulm Pharmacol Ther; 2000; 13(4):149-55. PubMed ID: 10930353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of prostaglandins and thromboxane A2 on coronary vessel tone--mechanisms of action and therapeutic implications.
    Schrör K
    Eur Heart J; 1993 Nov; 14 Suppl I():34-41. PubMed ID: 7507439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. F2-isoprostanes biomarkers of lipid peroxidation: their utility in evaluation of oxidative stress induced by toxic agents.
    Piłacik B; Nofer TW; Wasowicz W
    Int J Occup Med Environ Health; 2002; 15(1):19-27. PubMed ID: 12038860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of 8-epi-prostaglandin F(2alpha) in isolated rat kidney glomeruli by a radical-independent mechanism.
    Klein T; Neuhaus K; Reutter F; Nüsing RM
    Br J Pharmacol; 2001 Jul; 133(5):643-50. PubMed ID: 11429387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostanoids receptors signaling in different diseases/cancers progression.
    Yang Y; Tang LQ; Wei W
    J Recept Signal Transduct Res; 2013; 33(1):14-27. PubMed ID: 23327583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostanoid receptors: ontogeny and implications in vascular physiology.
    Wright DH; Abran D; Bhattacharya M; Hou X; Bernier SG; Bouayad A; Fouron JC; Vazquez-Tello A; Beauchamp MH; Clyman RI; Peri K; Varma DR; Chemtob S
    Am J Physiol Regul Integr Comp Physiol; 2001 Nov; 281(5):R1343-60. PubMed ID: 11641101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of oxidative modifications in atherosclerosis.
    Stocker R; Keaney JF
    Physiol Rev; 2004 Oct; 84(4):1381-478. PubMed ID: 15383655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid inflammatory mediators in diabetic vascular disease.
    Natarajan R; Nadler JL
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1542-8. PubMed ID: 15166011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.